IO Biotech, Inc.
IO Biotech, Inc. (IOBT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
iobt · stock forecast · 6 analysts (3M) · FMP · updated Apr 11, 2026
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.50
Consensus
$0.50
+12400.0% upside
Low
$0.50
Median: $0.5 · Last Close: $0.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.00 | ↓ 5.00% |
1-day model range: $0–$0. Peak: $0 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · IOBT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-26 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2025-10-22 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-09-30 | TD Cowen | Downgrade ↓ | Buy→Hold |
| 2025-09-29 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-08-12 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2025-04-01 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-09-16 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on IO Biotech, Inc. (IOBT) stock. Of the recent 26 rating actions, 0 were upgrades and 3 were downgrades. 6 analysts currently cover IOBT.
Analyst Recommendation Trends
IOBT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$14M
↓ 74.4% YoY
Revenue Next Year
$18M
↑ 28.6% YoY
EPS This Year
$-0.29
EPS Next Year
$-0.31
↑ 8.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast IOBT EPS of $-0.29 for the current fiscal year, based on estimates from 1 analysts. The IOBT revenue forecast is $14M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IOBT stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IOBT price target is $0.50 (+12400.0% upside), with an analyst consensus of Buy.
The IOBT short-term stock prediction for tomorrow is $0.00 (-5.00%).
IO Biotech, Inc. trades on NASDAQ under the ticker IOBT. The IOBT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
IOBT forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month IOBT price target is $0.50, with a high forecast of $0.50 and a low of $0.50. The median price target is shown in the chart above when available. This implies +12400.0% potential upside from the current price of $0.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.